contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


hansa-biopharma-ab-hansa-biopharma-to-host-q3-2025-interim-results-conference-call

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Hansa Biopharma er en svensk biotekvirksomhed imlifidase (Idefirix) som hovedproduktet. Imlifidase er et antistof-spaltende enzym, der udvikles til at muliggøre nyretransplantation hos stærkt sensibiliserede patienter. Enzymet kan videreudvikles til brug ved andre typer transplantation, i autoimmune sygdomme, genterapi og onkologi. Hidtil er Idefirix blevet betinget godkendt i EU til højsensibiliserede nyretransplanterede patienter.

I øjeblikket udfører Hansa et afgørende randomiseret kontrolforsøg i nyretransplantation i USA og forventer at påbegynde et yderligere afgørende studie på tværs af USA og EU i den sjældne autoimmune sygdom anti-GBM i løbet af 2022. Derudover fremmer Hansas forsknings- og udviklingsprogram enzymteknologien til at udvikle den næste generation af IgG-spaltende enzymer med potentielt lavere immunogenicitet, velegnet til gentagende dosering ved recidiverende autoimmune sygdomme og onkologi.

Hansa Biopharma

Lund, Sweden, 8 October, 2025. Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), will publish its interim report for January - September 2025 on Thursday 30 October, 2025. Interested parties...

Lund, Sweden, 8 October, 2025. Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), will publish its interim report for January - September 2025 on Thursday 30 October, 2025. Interested parties may join the Company's quarterly conference call on the same date at 13:00 CET / 8:00 EDT. The event will be hosted by Renée Aguiar-Lucander, CEO, Evan Ballantyne, CFO, Richard Philipson, CMO, and Maria Törnsén, COO and President U.S. The call will include a review of the interim results and a business and pipeline update. It will be held in English.  Slides used in the presentation will be made available on the company website at the following link: <a href="https://www.hansabiopharma.com/investors/financial-reports/">Financial reports | Hansa Biopharma</a>To participate in the telephone conference, please use the dial-in details provided below: Participant Dial In (Toll Free): 1-833-821-3542Participant International Dial In: 1-412-652-1248The webcast will be available on: <a href="https://event.choruscall.com/mediaframe/webcast.html?webcastid=Ff9aY2zz">Webcast | Hansa Biopharma Third Quarter Earnings</a>--- ENDS ---Contacts for more information:Evan Ballantyne,&nbsp;Chief Financial Officer IR@hansabiopharma.comKerstin Falck,&nbsp;VP Global Corporate Affairs media@hansabiopharma.comNotes to editorsAbout Hansa BiopharmaHansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company has a rich and expanding research and development program based on its proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in autoimmune diseases, gene therapy and transplantation. The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients and HNSA-5487, a next-generation IgG cleaving molecule with redosing potential. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at <a href="http://www.hansabiopharma.com">www.hansabiopharma.com</a> and follow us on <a href="https://www.linkedin.com/company/hansa-medical-ab/">LinkedIn</a>.©2025 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.<div></div>

Hansa Biopharma AB: Hansa Biopharma to host Q3 2025 interim results conference call